Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

UK Diagnostic Fret Over Loss of Support In Evidence Centers Restructure

Executive Summary

Changes are afoot for the four UK Diagnostic Evidence Co-operatives that help generate clinical and cost-effectiveness data for innovative IVDs. Companies worry it could mean diagnostic industry needs get lost among broad medtech targets. Also, a roundup of the British In Vitro Diagnostics Association's key priorities, including the EU IVD Regulation, procurement issues, antimicrobial resistance, and of course, Brexit, highlighted at the group's 2016 annual meeting.

You may also be interested in...



Diagnostics Marks 'NHS 70' With New UK Push On AMR

The National Health Service (NHS) came into being in the UK 70 years ago today, and to mark the occasion, NHS England and UK diagnostics stakeholders have officially launched a new prevention initiative: the UK AMR Diagnostic Collaborative. Its targeted actions and recommendations will help the NHS – and global systems – tackle the ever-larger-looming issue of antimicrobial resistance.

UK Medtech Market Access In Practice: Aim High But Stay Grounded

Manufacturers must ensure there are commercial outlets for the products they are developing, given the speed of change in medtech markets. That was the key message for companies and innovators at the UK Med-Tech Expo Conference 2017.

Amid Reforms, Brexit, UK IVD Firms Battle Funding And Adoption Issues

The EU In Vitro Diagnostics Regulation and Brexit loom large for UK IVD companies, but manufacturers serving the $1.6bn UK IVD market have many other competing concerns. It’s the most challenging period in more than 15 years, according to the British In Vitro Diagnostics Association Chief Executive Doris-Ann Williams.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

MT103972

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel